Multiple Myeloma | Specialty

Dr. Cho Discusses Role of Bispecific Agents in Myeloma

February 12th 2019

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses the role of bispecific agents in the treatment of patients with myeloma.

Dr. Holstein on Sequencing Strategies in Myeloma

February 8th 2019

Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska, discusses considerations for determining on optimal treatment sequence for patients with myeloma.

FDA Schedules ODAC Meeting for Selinexor in Penta-Refractory Myeloma

February 8th 2019

The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for February 26, 2019, to discuss a new drug application for selinexor in combination with dexamethasone for the treatment of patients with penta-refractory multiple myeloma.

Expert Highlights Ongoing Advances in Multiple Myeloma

February 7th 2019

Sarah Holstein, MD, PhD, highlights the vast treatment paradigm of myeloma and shared some considerations for sequencing.

Dr. Berdeja on Maintenance Therapy in Multiple Myeloma

February 7th 2019

Jesus Berdeja, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses maintenance therapy in multiple myeloma.

Dr. Valent on Ongoing Research With Immunotherapy in Multiple Myeloma

February 6th 2019

Jason Valent, MD, an oncologist at Cleveland Clinic, discusses ongoing research with immunotherapy, specifically checkpoint inhibitors, in the treatment of patients with multiple myeloma.

Isatuximab Triplet Improves PFS in Relapsed/Refractory Myeloma

February 5th 2019

Isatuximab in combination with pomalidomide (Pomalyst) and low-dose dexamethasone was shown to prolong progression-free survival compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Dr. Chari on Role of Immunotherapy in Myeloma

February 5th 2019

Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses the role of immunotherapy in the treatment of patients with myeloma.

Dr. Parekh on Potential Biomarker for Novel Drug in Myeloma

February 1st 2019

Samir Parekh, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses a promising potential biomarker for response to selinexor in patients with myeloma.

Chari Highlights Emerging Options in Heavily Pretreated Myeloma

January 26th 2019

Ajai Chari, MD, discusses novel treatment approaches for patients with heavily pretreated multiple myeloma.

Selinexor/Daratumumab Combo Shows Promise in Relapsed/Refractory Myeloma

January 22nd 2019

Cristina Gasparetto, MD, discusses the combination of daratumumab, selinexor, and dexamethasone in patients with multiple myeloma who have previously received ≥3 lines of therapy, which include an immunomodulatory agent and a proteasome inhibitor.

FDA Approval Sought for Daratumumab/Rd for Frontline Transplant-Ineligible Myeloma

January 22nd 2019

A supplemental Biologics License Application (sBLA) has been initiated with the FDA for daratumumab (Darzalex) for use in combination with lenalidomide (Revlimid) and dexamethasone (DRd) for the treatment of certain patients with multiple myeloma.

Dr. Jagannath on Treatment Advances in Transplant-Ineligible Patients With Myeloma

January 22nd 2019

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses the progress that has been made in transplant-ineligible patients with multiple myeloma.

PFS Benefit Confirmed With Daratumumab Plus VMP in Newly Diagnosed Myeloma

January 22nd 2019

Maria-Victoria Mateos, MD, PhD, discusses the updated findings from the ALCYONE trial in patients with newly diagnosed multiple myeloma.

Real-World Evidence Supports Split Daratumumab Dosing in Myeloma

January 21st 2019

Robert M. Rifkin, MD, highlights the results of a trial evaluating the safety of split-dosing administration of daratumumab in patients with multiple myeloma.

Dr. Chari on Treatment of Penta-Refractory Patients With Myeloma

January 19th 2019

Ajai Chari, MD, associate professor, Icahn School of Medicine, Mount Sinai Hospital, discusses the treatment of patients with penta-refractory multiple myeloma.

Dr. Wong on an Investigational Antibody-Drug Conjugate in Multiple Myeloma

January 18th 2019

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses an investigational antibody-drug conjugate (ADC) in multiple myeloma.

Controversy Adds Caution to CRISPR Editing in United States

January 17th 2019

The development of cancer treatments and diagnostic tools using CRISPR/Cas9 and other gene-editing technology is a promising area of research in the United States, although the field is moving into human studies at a relatively slow pace.

Novel Therapies Under Investigation in Multiple Myeloma

January 17th 2019

The ELOQUENT-3 Trial in R/R Multiple Myeloma

January 17th 2019